AZT: ArcticZymes enters RNA therapeutics market with two new enzymes targeting manufacturing and analytical efficiency

Tromsø, Norway - 27 October 2026 - ArcticZymes Technologies ASA (OSE: AZT) today
announced the early-access launch of RiboCleanT dsDNase and RiboCleaveT 1, its
first enzymes developed specifically for RNA therapeutics manufacturing and
analysis. The launch coincides with the opening of the 33rd ESGCT Annual
Congress at the Congress Centre Hamburg, Germany (27-30 October 2026).

As RNA therapeutics advance toward commercial-scale manufacturing, improving
process efficiency, reducing costs and simplifying analytical workflows are
becoming increasingly important. ArcticZymes' two new enzymes address these
challenges at critical stages of RNA manufacturing and quality analysis.

RiboCleanT dsDNase can be integrated directly into existing IVT workflows
without additional buffer or calcium and is modelled to reduce nuclease costs
per batch by more than 80%. RiboCleanT dsDNase delivered comparable DNA-removal
performance to reference DNase I while using 10 x fewer units, corresponding to
a 40-fold reduction in DNase protein mass added to the IVT workflow. Despite
using 10 times fewer enzyme units than DNase I, RiboCleanT dsDNase showed no
detectable difference in RNA integrity or yield under the tested conditions.

RiboCleaveT 1 simplifies sample preparation steps for mRNA cap-efficiency
analysis by replacing a multistep RNase H-based workflow with a single sequence
-specific digestion. Without requiring guide oligonucleotides, the enzyme
reduces sample preparation time from approximately six hours to 30 minutes,
while remaining compatible with existing analytical readout methods. This
streamlined approach is modelled to reduce total assay costs by more than 80%.

"RNA has proven it works. The challenge our customers now face is making it
faster, simpler and more cost-effective to develop and manufacture," said
Michael B. Akoh, CEO of ArcticZymes Technologies. "The launch of RiboClean
dsDNase and RiboCleave 1 demonstrates how we are delivering on our strategy to
diversify our product portfolio and expand into new markets, while applying our
proven enzyme expertise to deliver measurable improvements for our customers."

Both products are available to order now through ArcticZymes' open early-access
program. Visit ArcticZymes at ESGCT booth number D-06, go to
https://arcticzymes.com/advanced-therapies/rna-manufacturing, or contact
support@arcticzymes.com to find out more.

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh          Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll                    Tel +47 952 90187
                                     ir@arcticzymes.com

About ArcticZymes Technologies

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, in vitro diagnostics (IVD) and biomanufacturing.
The company has pioneered salt-active nucleases and continues to develop enzyme
solutions that support efficient and reliable production of advanced
therapeutics. www.arcticzymes.com
nt and reliable production of advanced\
therapeutics. www.arcticzymes.com\